Loading…

GC Corp.005250.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Major
Momentum neutral 54
Mkt cap
$321M
US dollars, full cap
Free float
43%
of shares outstanding
$/day
$434,453
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-3.7 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
125 days
23 Mar 2027
Close · KRW₩9,260
1D-2.0%
1W-4.5%
1M-3.3%
3M-13.9%
6M-44.9%
YTD-41.8%
1Y-42.6%
ATR %4.0%
52w lowhigh48.6% off high

What GC Corp. does

Employees: 163

GC Corp. at a glance

Size GC Corp. (005250.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $321M, the 465th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩9,260 on 18 Nov 2026.

Performance Over six months the shares fell 44.9%, against -20.4% for the median peer and -37.2% for the South Korea market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue grew 2.3% over the last twelve months (peer median +2.9%); the operating margin is 2.6% (peer median -0.8%).

Valuation It trades at 1.1× enterprise value to sales against a peer median of 4.1× (cheapest of 19).

Capital Return on invested capital runs 3.7 points below its cost of capital (5.0% WACC).

Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 79005250.KS 62
Six months, rebased to 100: GC Corp. against the median of its 20 peers (local-currency closes).

GC Corp. financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩2.45T₩2.45T₩2.20T₩2.06T₩2.08T
Revenue growth—+11%+7%-1%—
Gross profit₩704B₩660B₩600B₩564B₩667B
EBITDA₩173B₩142B₩92.8B₩73.4B₩150B
Net income-₩47.0B-₩69.5B₩24.0B-₩54.1B₩32.8B
Free cash flow-₩134B-₩86.6B-₩134B-₩130B₩23.9B
Capital expenditure₩126B₩150B₩57.7B₩133B₩127B
Total debt₩1.60T₩1.49T₩1.13T₩1.28T₩1.10T

Quarterly statements and history in the cockpit →

GC Corp. competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%0%+25%+50%SECAREAVIR368A600538INO002168INDSWFTLAB1720301509MYXALEMBICLTD1875SOLARARLMD005250.KS6-month return →1-month return →
Up and to the right = strong over both horizons. GC Corp. is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×500×SECARE6576INOINDSWFTLAB0007901875688302005250.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. GC Corp. is the large dot.

GC Corp. competitors and peer comparison

How GC Corp. compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

GC Corp. against its 20 peers (data as of 18 Nov 2026)
Measure005250.KSPeer medianRank in peer set
1-month return-3.3%-8.5%8th highest of 21
6-month return-44.9%-20.4%2nd lowest of 21
Distance from 52-week high-48.6%-37.5%7th lowest of 21
Revenue growth (TTM)+2.3%+2.9%8th lowest of 19
Operating margin2.6%-0.8%10th highest of 19
EV / Sales1.1×4.1×cheapest of 19
ROIC minus cost of capital-3.7 pp-7.7 pp7th highest of 18
EV / EBITDA16.0×12.6×3rd most expensive of 7
Net debt / EBITDA7.9×-1.8×most indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
GC Corp. 005250.KSSouth Korea$321M-45%+2%3%1.1×n/an/a
Swedencare SECARE.STSweden$321M-24%+3%7%1.8×6.1%+62.1%
Atea Pharmaceuticals AVIRUnited States$320M-5%n/an/an/an/an/a
Foresee Pharmaceuticals 6576.TWOTaiwan$322M-12%+6%-104%21.4×n/an/a
Kitazato 368A.TJapan$317M+7%+9%52%3.1×-16.8%+5.4%
Beihai Gofar Chuanshan Biological 600538.SSChina$326M-39%+10%-8%6.2×n/an/a
Inovio Pharmaceuticals INOUnited States$317M+37%+64%-25,954%921.6×n/an/a
Chongqing Hifuture Information Technology 002168.SZChina$326M-27%+2%-6%7.4×14.3%-14.0%
Ind-Swift Laboratories INDSWFTLAB.NSIndia$314M+150%+66%9%3.4×n/an/a
Standard Chemical & Pharmaceutical 1720.TWTaiwan$329M-1%+5%22%1.8×-11.5%+10.3%
Chengdu Huasun Technology 000790.SZChina$312M-20%-36%-57%5.6×27.5%-6.4%
Kingchem (Liaoning) Life Science 301509.SZChina$333M-28%+3%6%1.4×9.2%+6.5%
Mayne Pharma MYX.AXAustralia$333M+155%-6%-14%1.2×19.0%-0.9%
Alembic ALEMBICLTD.NSIndia$309M+25%-5%26%13.0×44.3%+26.7%
BioDlink International 1875.HKHong Kong$334M-24%-51%-31%4.8×n/an/a
Solara Active Pharma Sciences SOLARA.NSIndia$334M+12%+27%8%2.4×38.3%-3.2%
Enwei Pharmaceutical 301331.SZChina$308M-20%-7%5%2.1×14.0%+7.3%
Hinova Pharmaceuticals 688302.SSChina$305M-35%+251%-195%17.1×n/an/a
Relmada Therapeutics RLMDUnited States$305M-60%n/an/an/an/an/a
Honz Pharmaceutical 300086.SZChina$299M-40%-23%-54%7.3×56.0%-12.8%
Zhejiang Shengda Bio-Pharm 603079.SSChina$297M-30%-3%7%2.3×4.6%-0.3%

Questions

Which companies are GC Corp.'s closest peers?
The cockpit's peer set: Swedencare (SECARE.ST), Atea Pharmaceuticals (AVIR), Foresee Pharmaceuticals (6576.TWO), Kitazato (368A.T), Beihai Gofar Chuanshan Biological (600538.SS), Inovio Pharmaceuticals (INO), Chongqing Hifuture Information Technology (002168.SZ), Ind-Swift Laboratories (INDSWFTLAB.NS).
Is GC Corp. expensive compared with its peers?
On ev / sales it trades at 1.1× against a peer median of 4.1×, cheapest of 19 in its peer set.
How has GC Corp. stock performed?
Over six months to 18 Nov 2026 the shares returned -44.9% against -20.4% for the median peer; over one year -42.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.